UNSPSC 51262912: Mepindolol sulfate

This classification denotes a beta-adrenergic blocking agent 2C15H22N2O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63523X4FBA, chemically known as 2-propanol, 1-((1-methylethyl)amino)-3-((2-methyl-1h-indol-4-yl)oxy)-, sulfate (2:1), but more generally known as mepindolol sulfate, which bears US NIH Compound Identifier 6917859. European Medicines Agency schedules Mepindolol sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03157MIG.

Most nations, for tariff and trade purposes, schedule mepindolol sulfate under HS 29339990 and SITC 51577. As of Q4 2014, MEPINDOLOL SULFATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CC2C([NH]1)CCCC2OCC(CNC(C)C)O.CC1CC2C([NH]1)CCCC2OCC(CNC(C)C)O.OS(=O)(=O)O.

UNSPSC 51262912 Mepindolol sulfate (Commodity) represents pharmaceutical products that state and local governments procure for community health and emergency response programs. The recent state and local activity under this code, however, shows a mismatch: Seminole County, Florida posted an IFB in June 2026 for naloxone and drug deactivation systems — opioid-antagonist medications and harm-reduction equipment — rather than mepindolol sulfate, a beta-blocker used in cardiovascular treatment. The solicitation reveals that counties are buying pharmaceuticals and medical systems in volume for public health initiatives, with multi-year contract terms, quarterly delivery cycles, and compliance requirements including E-Verify, drug-free workplace certification, and federal funding compliance when FEMA support is involved. Issuing bodies under this code span county health departments and community health programs focused on emergency medical response and public health support.

The code shows limited recent activity aligned with its nominal scope. The single posted opportunity — Seminole County's IFB 60459723LAS, due July 26, 2023, for 1,900 units of naloxone and 800 drug deactivation systems annually — does not represent mepindolol procurement. Geographic activity is concentrated in Florida based on available records, though the sparse posting volume suggests this Commodity code sees minimal state and local procurement attention overall. Vendors pursuing opportunities under this code should monitor county health departments and regional public health authorities in Florida and adjacent states for emergency medical supply and pharmaceutical procurement, though the disconnect between the code's pharmaceutical classification and the actual naloxone-focused solicitation signals potential classification inconsistency in the sourcing agency's procurement system.